Relationship between somatic mutations and the response to the treatment of de novo patients with myelodysplastic syndromes: reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.01.012
- VernacularTitle:初发骨髓增生异常综合征患者体细胞突变与治疗反应的关系:第57届美国血液学会年会报道
- Author:
Xudong TANG
;
Lu ZHANG
;
Yufeng TANG
;
Dexiu WANG
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndromes;
Somatic mutations;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(1):42-44
- CountryChina
- Language:Chinese
-
Abstract:
Research progress of somatic mutations and the response to the treatment of de novo myelodysplastic syndromes (MDS) patients in the 57th American Society of Hematology (ASH) annual meetings was reviewed. The optimal methods and therapy time for patients with high-risk de novo MDS remained an area of ongoing investigation. The clinical prognostic scoring system does not include the molecular genetic abnormalities and DNA metlylation of histone/nuclear chromatin modifications, which may predict the effect of hypomethylation (HMA). Treatment of HMA may change the expression of genes related with prognosis, and the response rate to the HMA treatment was significantly increased for TET2-mutated patients with high-variant allele frequencies. The overall grade of recommendation for choosing HMA therapy over induction chemotherapy in high-risk MDS based on molecular genetic mutations was 2C, according to less-associated toxicity and increased responses primarily in TET2-mutated disease. Further prospective studies are needed to evaluate the long-term effects of HMA therapy, particularly in TET2-mutated patients.
